Occuity secures UK and European distribution
Ahead of the launch of the PM1 Pachymeter, Occuity has signed a number of distribution partnership agreements
14 July 2023
Medical technology company, Occuity, has signed distributor partnership agreements in the UK and Europe ahead of the launch of the PM1 Pachymeter.
The non-contact, handheld device is expected to launch this summer, and is currently in the process of CE-marking.
Occuity has partnered with Birmingham Optical for distribution in the UK.
Commenting on how the company would be helping to introduce the PM1 to the UK market, Amanda Higginbotham, chief commercial officer at Birmingham Optical, said: “With their non-contact, handheld platform, Occuity has an exciting pipeline of future products including the AX1 Axiometer for Myopia Management, and we look forward to working with them.”
Occuity has signed further distribution agreements across Europe, including: E. Janach, Italy; bon Optic, Germany; Medilens, Sweden, Denmark and Norway; and Iogen Oy, Finland, Latvia and Estonia.
Up close: the PM1 Pachymeter
OT received a demonstration of Occuity’s PM1 Pachymeter at 100% Optical 2023. Take a look here.
Discussions are underway with distributors covering the Asia Pacific and North American territories, Occuity said.
Commenting on the upcoming launch, Dan Daly, CEO of Occuity, said the company was looking forward to introducing the PM1 to the market.
“Having completed successful clinical trials and submitted for CE certification, we are confident in its exceptional performance,” he said. “Through discussions with distributors across Europe, we believe there will be significant demand for the PM1 and have therefore carefully chosen partners who share our dedication to delivering exceptional ophthalmic devices."
Clinical trial results on the Occuity PM1 were published in the Journal of Ophthalmic & Physiological Optics at the end of June.
The study analysed the repeatability of central corneal thickness measurements taken with the PM1 pachymeter and assessed its agreement with ultrasound biometry and two commercially-available optical biometers in participants with normal eyes.
The trial was carried out by a team of optometrists including Professor John Lawrenson at City University, Simranjit Gill, Isra Masuid and Fardip Rashid of Moorfields Eye Hospital.
It involved taking consecutive measurements of the right eye of 105 participants with different devices, including the PM1.
The report highlighted that the device showed “excellent precision for central corneal thickness measurements across a range of corneal thicknesses in normal eyes and provides a safe and easy-to-use alternative to ultrasound pachymetry.”